Percheron Therapeutics Limited

ASX:PER Rapporto sulle azioni

Cap. di mercato: AU$70.3m

Percheron Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Percheron Therapeutics has a total shareholder equity of A$9.4M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$14.5M and A$5.2M respectively.

Informazioni chiave

0%

Rapporto debito/patrimonio netto

AU$0

Debito

Indice di copertura degli interessin/a
ContantiAU$11.87m
Patrimonio nettoAU$9.36m
Totale passivitàAU$5.17m
Totale attivitàAU$14.53m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03
We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Jun 08
We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Feb 14
We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Aug 26
We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24
Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11
We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26
Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Analisi della posizione finanziaria

Passività a breve termine: PER's short term assets (A$14.5M) exceed its short term liabilities (A$5.2M).

Passività a lungo termine: PER's short term assets (A$14.5M) exceed its long term liabilities (A$15.2K).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: PER is debt free.

Riduzione del debito: PER had no debt 5 years ago.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: PER has sufficient cash runway for more than a year based on its current free cash flow.

Previsione Cash Runway: PER is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.


Scoprire le aziende sane